# US 2024/0122876 A1 · Compositions and methods for the treatment of ocular disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0122876 A1
- Document ID: US20240122876A1
- Status: Published application
- Kind: A1
- Application number: 18/263,758
- Filed: 2022-02-01
- Published: 2024-04-18
- Earliest claimed: 2021-02-01
- Assignees: Case Western Reserve University; The Regents of the University of California; The United States Government as represented by the Department of Veterans Affairs
- Applicants: Case Western Reserve University; The Regents of the University of California
- Inventors: Gregory Tochtrop; Philip Kiser; Jianye Zhang; Krzysztof Palczewski
- Web page: https://patentgrep.com/patent/US20240122876A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- C07C 217/72: linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- A61P 27/02: Ophthalmic agents
- C07B 59/001: {Acyclic or carbocyclic compounds}
- C07C 2601/14: The ring being saturated
- C07C 2601/16: the ring being unsaturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or solvate thereof.

## Claims

### Claim 1

A method of treating an ocular disorder in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of a compound of formula (1):
or a pharmaceutically acceptable salt, tautomer, or solvate thereof;
wherein n is an integer from 0 to 6;
R1 is a substituted or unsubstituted C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C12 aryl, heteroaryl, heterocyclyl, or C6-C12 alkaryl;
R2, R4, and R5 are each independently H or F;
R3 is H, F, or an alkyl or a fluoro alkyl group that includes at least three carbon atoms;
R6 is H, CH3, or OH;
R7 and R8 are H or D, wherein at least one of R7 or R8 is D if R2, R4, and R5 are H; and
the dashed line is an optional bond.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least one of R7 or R8 is D.

### Claim 3 (depends on 1)

The method of claim 1, wherein both of R7 and R8 are D.

### Claim 4 (depends on 1)

The method of claim 1, wherein at least one of R2 or R5 is F.

### Claim 5 (depends on 4)

The method of claim 4, wherein R2 is F.

### Claim 6 (depends on 1)

The method of claim 1, wherein R1 is selected from the group consisting of:
and fluoro derivatives thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein R1 is selected from the group consisting of:
and fluoro derivatives thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein R3 is a branched or cyclic C3-C24 alkyl or fluoroalkyl.

### Claim 9 (depends on 1)

The method of claim 1, wherein R3 is selected from the group consisting of:
and fluoro derivatives thereof.

### Claim at position 10

10-22. (canceled)

### Claim 23

A method of treating an ocular disorder in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of a compound of formula (IV):
or a pharmaceutically acceptable salt, tautomer, or solvate thereof;
wherein R1 is a substituted or unsubstituted C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C12 aryl, heteroaryl, heterocyclyl, or C6-C12 alkaryl;
R2 and R4 are each independently H or F; and
R3 is H, F, or an alkyl or a fluoro alkyl group that includes at least three carbon atoms.

### Claim 24 (depends on 23)

The method of claim 23, wherein R2 is F.

### Claim 25 (depends on 23)

The method of claim 23, wherein R1 is selected from the group consisting of:
and fluoro derivatives thereof.

### Claim 26 (depends on 23)

The method of claim 23, wherein R1 is selected from the group consisting of:
and fluoro derivatives thereof.

### Claim 27 (depends on 23)

The method of claim 23, wherein R3 is a branched or cyclic C3-C24 alkyl or fluoroalkyl.

### Claim 28 (depends on 27)

The method of claim 27, wherein R3 is selected from the group consisting of:
and fluoro derivatives thereof.

### Claim at position 17

29-36. (canceled)

### Claim 37

A method of treating an ocular disorder in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of a compound selected from:
or a pharmaceutically acceptable salt, tautomer, or solvate thereof.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 1)

The method of claim 1, the compound being delivered to the subject by at least one of topical administration, systemic administration, intravitreal injection, and intraocular delivery.

### Claim 41

(canceled)

### Claim 42 (depends on 1)

The method of claim 1, the ocular disorder comprising at least one of light induced retinal degeneration, macular degeneration, Stargardt's disease, geographic atrophy, and retinitis pigmentosa.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)
